Class effects of SGLT2 inhibitors on cardiorenal outcomes

BACKGROUND: To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mell...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cardiovasc Diabetol
Autori principali: Kluger, Aaron Y., Tecson, Kristen M., Lee, Andy Y., Lerma, Edgar V., Rangaswami, Janani, Lepor, Norman E., Cobble, Michael E., McCullough, Peter A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6683461/
https://ncbi.nlm.nih.gov/pubmed/31382965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0903-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi